Last reviewed · How we verify
Mevac-A vaccine
Mevac-A is a therapeutic vaccine designed to stimulate immune responses against mevalonate pathway-associated antigens to treat cancer.
Mevac-A is a therapeutic vaccine designed to stimulate immune responses against mevalonate pathway-associated antigens to treat cancer. Used for Cancer (specific indication under investigation in phase 3).
At a glance
| Generic name | Mevac-A vaccine |
|---|---|
| Sponsor | Chiang Mai University |
| Drug class | Therapeutic cancer vaccine |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The vaccine targets antigens related to the mevalonate metabolic pathway, which is often dysregulated in cancer cells. By inducing cellular and humoral immune responses against these pathway-associated targets, the vaccine aims to enable the immune system to recognize and eliminate cancer cells. This approach leverages the metabolic vulnerabilities of malignant cells.
Approved indications
- Cancer (specific indication under investigation in phase 3)
Common side effects
- Injection site reactions
- Fever
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mevac-A vaccine CI brief — competitive landscape report
- Mevac-A vaccine updates RSS · CI watch RSS
- Chiang Mai University portfolio CI